scholarly journals Differences in the Apparent Metabolic Clearance Rate of Testosterone in Young and Older Men with Gonadotropin Suppression Receiving Graded Doses of Testosterone

2006 ◽  
Vol 91 (11) ◽  
pp. 4669-4675 ◽  
Author(s):  
Andrea D. Coviello ◽  
Kishore Lakshman ◽  
Norman A. Mazer ◽  
Shalender Bhasin
Keyword(s):  
Lean Body Mass ◽  
Body Mass ◽  
Young Men ◽  
Serum Testosterone ◽  
Older Men ◽  
Total Testosterone ◽  
Metabolic Clearance ◽  
Clearance Rates ◽  
Testosterone Levels ◽  
Age Related

Abstract Background: Recently we found that testosterone levels are higher in older men than young men receiving exogenous testosterone. We hypothesized that older men have lower apparent testosterone metabolic clearance rates (aMCR-T) that contribute to higher testosterone levels. Objective: The objective of the study was to compare aMCR-T in older and young men and identify predictors of aMCR-T. Methods: Sixty-one younger (19–35 yr) and 60 older (59–75 yr) men were given a monthly GnRH agonist and weekly testosterone enanthate (TE) (25, 50, 125, 300, or 600 mg) for 5 months. Estimated aMCR-T was calculated from the amount of TE delivered weekly and trough serum testosterone concentrations, corrected for real-time absorption kinetics from the im testosterone depot. Results: Older men had lower total (316 ± 13 vs. 585 ± 26 ng/dl, P < 0.00001) and free testosterone (4 ± 0.1 vs. 6 ± 0.3 ng/dl, P < 0.00001) and higher SHBG (52 ± 3 vs. 33 ± 2 nmol/liter, P < 0.00001) than younger men at baseline. Total and free testosterones increased with TE dose and were higher in older men than young men in the 125-, 300-, and 600-mg dose groups. aMCR-T was lower in older men than young men (1390 ± 69 vs. 1821 ± 102 liter/d, P = 0.006). aMCR-T correlated negatively with age (P = 0.0007), SHBG (P = 0.046), and total testosterone during treatment (P = 0.02) and percent body fat at baseline (P = 0.01) and during treatment (P = 0.004). aMCR-T correlated positively with lean body mass at baseline (P = 0.03) and during treatment (P = 0.01). In multiple regression models, significant predictors of aMCR-T included lean body mass (P = 0.008), percent fat mass (P = 0.009), and SHBG (P = 0.001). Conclusions: Higher testosterone levels in older men receiving TE were associated with an age-related decrease in apparent testosterone metabolic clearance rates. Body composition and SHBG were significant predictors of aMCR-T.

scholarly journals Furosap, a novel Fenugreek seed extract improves lean body mass and serum testosterone in a randomized, placebo-controlled, double-blind clinical investigation

2018 ◽  
Vol 8 (11) ◽  
pp. 519 ◽  
Author(s):  
Rui Guo ◽  
Qiurong Wang ◽  
Rama P. Nair ◽  
Scarlet L. Barnes ◽  
Derek T. Smith ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Lean Body Mass ◽  
Body Mass ◽  
Testosterone Level ◽  
Serum Testosterone ◽  
Seed Extract ◽  
Fat Free Mass ◽  
Total Testosterone ◽  
Double Blind ◽  
Fenugreek Seed

Background: The Indian spice fenugreek (Trigonella foenum-graecum) has been credited with numerous health benefits in cardiovascular disorders, metabolic syndrome, inflammatory conditions, glucose-insulin regulation, and sports performance. Previous studies from our laboratories demonstrated that fenugreek seed extract improved glucose tolerance, insulin sensitivity, augmented serum testosterone level and improved cardiovascular functions. Our investigation examined the efficacy of Furosap, a novel fenugreek seed extract enriched in 20% protodioscin, on exercise performance. Methods: This randomized, double-blind, placebo-controlled, clinical study was conducted in forty healthy male athletes (n = 40) over a period of 12 consecutive weeks. Subjects were given either placebo or Furosap capsules (250 mg/day b.d.) and serum samples were used to assess serum total testosterone level and C-reactive proteins (CRP) at baseline and at the end of 12-weeks of treatment. Body fat mass, lean mass, fat mass, fat-free mass, grip strength, upper and lower body strength, maximal graded exercise stress using a digital hand dynamometer, dual-energy X-ray absorptiometry (DEXA), force plate, and treadmill with open-circuit spirometry were assessed at the baseline and at the end of 12-weeks of treatment.Results: Furosap supplementation significantly increased mean lean body mass and fat-free mass compared to subjects receiving placebo. Additionally, Furosap-treated subjects elevated serum testosterone levels. Furosap supplemented subjects also exhibited a tendency towards lowering blood pressure during exhaustion. No adverse reports were reported.Conclusions: Given improvement of lean body mass and serum total testosterone following intervention with Furosap, Furosap likely has benefits for exercise endurance and sports medicine. Keywords: Fenugreek seed extract; safety; body mass; fat-free mass; blood pressure; muscle strength.

scholarly journals Testosterone Therapy for Men With Age-Related Low Testosterone: Tempest in a Teacup

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. 471-471
Author(s):  
Shehzad Basaria
Keyword(s):  
Cardiovascular Health ◽  
Serum Testosterone ◽  
Older Men ◽  
Normal Range ◽  
Testosterone Levels ◽  
Age Related ◽  
Calcified Plaque ◽  
Testosterone Gel ◽  
Physical Dysfunction ◽  
Low Testosterone

Abstract Serum testosterone concentrations decrease in men with age, but benefits and risks of raising testosterone levels in older men remain controversial. In the T-Trials, a total of 790 men, age 65 and older, with a serum testosterone concentration of < 275 ng/dL and symptoms of sexual dysfunction, fatigue or physical dysfunction were randomized to either testosterone gel or placebo gel for 1 year. Treatment in the testosterone arm increased serum testosterone levels to the mid-normal range for young men. Testosterone replacement was associated with a significant increase in sexual activity (p<0.001), libido and erectile function. In contrast, there was no improvement in vitality or physical function. Adverse findings included increases in non-calcified plaque formation and a higher rate of prostate events. In sum, testosterone treatment in older men was associated with modest benefits, while the risk on prostate and cardiovascular health remain unclear.

scholarly journals Long-Term Testosterone Supplementation in Older Men Attenuates Age-Related Decline in Aerobic Capacity

2018 ◽  
Vol 103 (8) ◽  
pp. 2861-2869 ◽  
Author(s):  
Tinna Traustadóttir ◽  
S Mitchell Harman ◽  
Panayiotis Tsitouras ◽  
Karol M Pencina ◽  
Zhuoying Li ◽  
...  
Keyword(s):  
Aerobic Capacity ◽  
Older Men ◽  
Total Testosterone ◽  
Long Term Effects ◽  
Double Blind ◽  
Testosterone Levels ◽  
Age Related ◽  
Aging Men ◽  
The Difference

Abstract Context Testosterone increases skeletal muscle mass and strength, but long-term effects of testosterone supplementation on aerobic capacity, or peak oxygen uptake (V̇O2peak), in healthy older men with low testosterone have not been evaluated. Objective To determine the effects of testosterone supplementation on V̇O2peak during incremental cycle ergometry. Design A double-blind, randomized, placebo-controlled, parallel-group trial (Testosterone’s Effects on Atherosclerosis Progression in Aging Men). Setting Exercise physiology laboratory. Participants Healthy men aged ≥ 60 years with total testosterone levels of 100 to 400 ng/dL (3.5 to 13.9 nmol/L) or free testosterone levels < 50 pg/mL (174 pmol/L). Interventions Randomization to 1% transdermal testosterone gel adjusted to achieve serum levels of 500 to 950 ng/dL or placebo applied daily for 3 years. Main Outcome Measures Change in V̇O2peak. Results Mean (±SD) baseline V̇O2peak was 24.2 ± 5.2 and 23.6 ± 5.6 mL/kg/min for testosterone and placebo, respectively. V̇O2peak did not change in men treated with testosterone but fell significantly in men receiving placebo (average 3-year decrease, 0.88 mL/kg/min; 95% CI, −1.39 to 0.38 mL/kg/min; P = 0.035); the difference in change in V̇O2peak between groups was significant (average 3-year difference, 0.91 mL/kg/min; 95% CI, 0.010 to 0.122 mL/kg/min; P = 0.008). The 1-g/dL mean increase in hemoglobin (P < 0.001) was significantly associated with changes in V̇O2peak in testosterone-treated men. Conclusion The mean 3-year change in V̇O2peak was significantly smaller in men treated with testosterone than in men receiving placebo and was associated with increases in hemoglobin. The difference in V̇O2peak change between groups may indicate attenuation of its expected age-related decline; the clinical meaningfulness of the modest treatment effect remains to be determined.

115 EXOGENOUS TESTOSTERONE ALONE OR WITH FINASTERIDE INCREASES PHYSICAL PERFORMANCE, GRIP STRENGTH, AND LEAN BODY MASS IN OLDER MEN WITH LOW SERUM TESTOSTERONE

2005 ◽  
Vol 53 (1) ◽  
pp. S97.4-S97
Author(s):  
S. T. Page ◽  
J. K. Amory ◽  
F. D. Bowman ◽  
B. D. Anawalt ◽  
A. M. Matsumoto ◽  
...  
Keyword(s):  
Grip Strength ◽  
Lean Body Mass ◽  
Physical Performance ◽  
Body Mass ◽  
Serum Testosterone ◽  
Older Men ◽  
Low Serum

scholarly journals Higher Testosterone Levels Are Associated with Less Loss of Lean Body Mass in Older Men

2011 ◽  
Vol 96 (12) ◽  
pp. 3855-3863 ◽  
Author(s):  
Erin S. LeBlanc ◽  
Patty Y. Wang ◽  
Christine G. Lee ◽  
Elizabeth Barrett-Connor ◽  
Jane A. Cauley ◽  
...  
Keyword(s):  
Lean Body Mass ◽  
Body Mass ◽  
Older Men ◽  
Testosterone Levels

scholarly journals The Association of Testosterone Levels with Overall Sleep Quality, Sleep Architecture, and Sleep-Disordered Breathing

2008 ◽  
Vol 93 (7) ◽  
pp. 2602-2609 ◽  
Author(s):  
Elizabeth Barrett-Connor ◽  
Thuy-Tien Dam ◽  
Katie Stone ◽  
Stephanie Litwack Harrison ◽  
Susan Redline ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Sleep Apnea ◽  
Body Mass ◽  
Sleep Disordered Breathing ◽  
Older Men ◽  
Sleep Efficiency ◽  
Total Testosterone ◽  
Testosterone Levels ◽  
Low Testosterone ◽  
Disordered Breathing

Abstract Context: Little is known about the association of low endogenous testosterone levels and abnormal sleep patterns in older men, although pharmacological doses of testosterone are associated with increased severity of sleep apnea and other sleep disturbances. Objective: The objective of the study was to examine the association between serum testosterone levels with objectively measured sleep characteristics. Design: This was a cohort study. Setting: Community-dwelling men aged 65 yr or older from six clinical centers in the United States participated in the study. Participants and Main Outcome Measures: A total of 1312 men had baseline total testosterone levels measured in 2000–2002, followed 3.4 yr later by 72-h (minimum) actigraphy and one-night in-home polysomnography to assess sleep duration, sleep fragmentation, and sleep apnea. Analyses were performed by quartile of total testosterone and categorically defined low vs. higher total testosterone (&lt;250 ng/dl vs. ≥250 ng/dl). Lifestyle and body size were covariates. Results: Total testosterone levels were unrelated to age or duration of sleep. Men with lower testosterone levels had lower sleep efficiency, with increased nocturnal awakenings and less time in slow-wave sleep as well as a higher apnea-hypopnea index and more sleep time with O2 saturation levels below 90%. Low testosterone levels were associated with overweight, and all significant associations were attenuated or absent after adjusting for body mass index or waist circumference. In a post hoc analysis in men with higher body mass index (&gt;27 kg/m2), testosterone was significantly associated with more periods awake after sleep onset and lower sleep efficiency. Conclusion: Low total testosterone levels are associated with less healthy sleep in older men. This association is largely explained by adiposity. Clinical trials are necessary to determine whether body weight acts directly or indirectly (via low testosterone) in the causal pathway for sleep-disordered breathing in older men.

scholarly journals Hypothalamic Response to Kisspeptin-54 and Pituitary Response to Gonadotropin-Releasing Hormone Are Preserved in Healthy Older Men

2018 ◽  
Vol 106 (4) ◽  
pp. 401-410 ◽  
Author(s):  
Ali Abbara ◽  
Shakunthala Narayanaswamy ◽  
Chioma Izzi-Engbeaya ◽  
Alexander N. Comninos ◽  
Sophie A. Clarke ◽  
...  
Keyword(s):  
Late Onset ◽  
Follicle Stimulating Hormone ◽  
Young Men ◽  
Serum Testosterone ◽  
Older Men ◽  
Gonadotropin Releasing Hormone ◽  
Total Testosterone ◽  
Releasing Hormone ◽  
Serum Gonadotropin ◽  
Similar Body

Background: Male testosterone levels decline by 1% per year from the age of 40 years. Whilst a primary testicular deficit occurs, hypothalamic or pituitary dysregulation may also coexist. This study aimed to compare the hypothalamic response to kisspeptin-54 and the pituitary response to gonadotropin-releasing hormone (GnRH) of older men with those of young men. Methods: Following 1 h of baseline sampling, healthy older men (n = 5, mean age 59.3 ± 2.9 years) received a 3-h intravenous infusion of either vehicle, kisspeptin-54 0.1, 0.3, or 1.0 nmol/kg/h or GnRH 0.1 nmol/kg/h, on five different study days. Serum gonadotropins and total testosterone were measured every 10 min and compared to those of young men (n = 5/group) (mean age 28.9 ± 2.0 years) with a similar body mass index (24 kg/m2) who underwent the same protocol. Results: Kisspeptin-54 and GnRH significantly stimulated serum gonadotropin release in older men compared to vehicle (p < 0.001 for all groups). Gonadotropin response to kisspeptin-54 was at least preserved in older men when compared to young men. At the highest dose of kisspeptin-54 (1.0 nmol/kg/h), a significantly greater luteinising hormone (LH) (p = 0.003) response was observed in older men. The follicle-stimulating hormone (FSH) response to GnRH was increased in older men (p = 0.002), but the LH response was similar (p = 0.38). Serum testosterone rises following all doses of kisspeptin-54 (p ≤ 0.009) were reduced in older men. Conclusions: Our data suggest that healthy older men without late-onset hypo­gonadism (LOH) have preserved hypothalamic response to kisspeptin-54 and pituitary response to GnRH, but impaired testicular response. Further work is required to investigate the use of kisspeptin-54 to identify hypothalamic deficits in men with LOH.

Why Do We Need New Markers for Male Hypogonadism and How Seminal Proteomics Might Solve the Problem?

2020 ◽  
Vol 27 (12) ◽  
pp. 1186-1191
Author(s):  
Giuseppe Grande ◽  
Domenico Milardi ◽  
Silvia Baroni ◽  
Andrea Urbani ◽  
Alfredo Pontecorvi
Keyword(s):  
Serum Testosterone ◽  
Clinical Syndrome ◽  
Testosterone Replacement ◽  
Total Testosterone ◽  
Male Hypogonadism ◽  
Grey Zone ◽  
Testosterone Levels ◽  
Normal Number ◽  
Replacement Treatment

Male hypogonadism is “a clinical syndrome that results from failure of the testis to produce physiological concentrations of testosterone and/or a normal number of spermatozoa due to pathology at one or more levels of the hypothalamic– pituitary–testicular axis”. The diagnostic protocol of male hypogonadism includes accurate medical history, physical exam, as well as hormone assays and instrumental evaluation. Basal hormonal evaluation of serum testosterone, LH, and FSH is important in the evaluation of diseases of the hypothalamus-pituitary-testis axis. Total testosterone levels < 8 nmol/l profoundly suggest the diagnosis of hypogonadism. An inadequate androgen status is moreover possible if the total testosterone levels are 8-12 nmol/L. In this “grey zone” the diagnosis of hypogonadism is debated and the appropriateness for treating these patients with testosterone should be fostered by symptoms, although often non-specific. Up to now, no markers of androgen tissue action can be used in clinical practice. The identification of markers of androgens action might be useful in supporting diagnosis, Testosterone Replacement Treatment (TRT) and clinical follow-up. The aim of this review is to analyze the main findings of recent studies in the field of discovering putative diagnostic markers of male hypogonadism in seminal plasma by proteomic techniques. The identified proteins might represent a “molecular androtest” useful as a seminal fingerprint of male hypogonadism, for the diagnosis of patients with moderate grades of testosterone reduction and in the follow-up of testosterone replacement treatment.

scholarly journals Effect of oral DHEA on serum testosterone and adaptations to resistance training in young men

1999 ◽  
Vol 87 (6) ◽  
pp. 2274-2283 ◽  
Author(s):  
Gregory A. Brown ◽  
Matthew D. Vukovich ◽  
Rick L. Sharp ◽  
Tracy A. Reifenrath ◽  
Kerry A. Parsons ◽  
...  
Keyword(s):  
Resistance Training ◽  
Young Men ◽  
Serum Testosterone ◽  
Treated Group ◽  
Whole Body ◽  
Total Testosterone ◽  
Resistance Training Program ◽  
Body Resistance ◽  
Liver Transaminases ◽  
And Training

This study examined the effects of acute dehydroepiandrosterone (DHEA) ingestion on serum steroid hormones and the effect of chronic DHEA intake on the adaptations to resistance training. In 10 young men (23 ± 4 yr old), ingestion of 50 mg of DHEA increased serum androstenedione concentrations 150% within 60 min ( P < 0.05) but did not affect serum testosterone and estrogen concentrations. An additional 19 men (23 ± 1 yr old) participated in an 8-wk whole body resistance-training program and ingested DHEA (150 mg/day, n = 9) or placebo ( n = 10) during weeks 1, 2, 4, 5, 7, and 8. Serum androstenedione concentrations were significantly ( P < 0.05) increased in the DHEA-treated group after 2 and 5 wk. Serum concentrations of free and total testosterone, estrone, estradiol, estriol, lipids, and liver transaminases were unaffected by supplementation and training, while strength and lean body mass increased significantly and similarly ( P < 0.05) in the men treated with placebo and DHEA. These results suggest that DHEA ingestion does not enhance serum testosterone concentrations or adaptations associated with resistance training in young men.

scholarly journals In men older than 70 years, total testosterone remains stable while free testosterone declines with age. The Health in Men Study

2007 ◽  
Vol 156 (5) ◽  
pp. 585-594 ◽  
Author(s):  
Bu B Yeap ◽  
Osvaldo P Almeida ◽  
Zoë Hyde ◽  
Paul E Norman ◽  
S A Paul Chubb ◽  
...  
Keyword(s):  
Free Testosterone ◽  
Older Men ◽  
Early Morning ◽  
Sex Hormone Binding Globulin ◽  
Total Testosterone ◽  
Limited Data ◽  
Cross Sectional ◽  
Testosterone Concentration ◽  
Age Related ◽  
Clinical Consequences

Objective: An age-related decline in serum total and free testosterone concentration may contribute to ill health in men, but limited data are available for men > 70 years of age. We sought to determine the distribution and associations of reduced testosterone concentrations in older men. Design: The Health in Men Study is a community-representative prospective cohort investigation of 4263 men aged ≥ 70 years. Cross-sectional hormone data from 3645 men were analysed. Methods: Early morning sera were assayed for total testosterone, sex hormone binding globulin (SHBG) and LH. Free testosterone was calculated using the Vermeulen method. Results: Mean (± s.d.) serum total testosterone was 15.4 ± 5.6 nmol/l (444 ± 162 ng/dl), SHBG 42.4 ± 16.7 nmol/l and free testosterone 278 ± 96 pmol/l (8.01 ± 2.78 ng/dl). Total testosterone correlated with SHBG (Spearman’s r = 0.6, P < 0.0001). LH and SHBG increased with age (r = 0.2, P < 0.0001 for both). Instead of declining, total testosterone increased marginally (r = 0.04, P = 0.007) whilst free testosterone declined with age (r = −0.1, P < 0.0001). Free testosterone was inversely correlated with LH (r = −0.1, P < 0.0001). In multivariate analyses, increasing age, body mass index (BMI) and LH were associated with lower free testosterone. Conclusions: In men aged 70–89 years, modulation of androgen action may occur via an age-related increase in SHBG and reduction in free testosterone without a decline in total testosterone concentration. Increasing age, BMI and LH are independently associated with lower free testosterone. Further investigation would be required to assess the clinical consequences of low serum free testosterone, particularly in older men in whom total testosterone may be preserved.

Sign in / Sign up

Export Citation Format

Share Document